Qiao, Y., Ye, Y., Cai, T., Li, S
BREAKING NEWS APRIL 15, 2026 - In a welcome announcement to the SSRP community, the FDA reported today that it will imminently remove the following bulk drug substances from category 2: BPC-157, LL-37, DiHexa, DSIP, Epitalon, *GHK-Cu (injectable only), KPV, PEG-MGF, Melanotan II, MOTs-C, Semax, and TB-500
In 2025, compounding surged in the US as a workaround during GLP-1 shortages, with telehealth providers stepping in to meet demand
Half-life Terminal half-life of ~37 hours reported for the SC implant formulation in EMA review documentation, consistent with the prolonged activity noted by Sawyer et al
Exposure time: 10s
She also argued that diabetes is a risk factor for NAION